SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 14, 2006--Hana Biosciences (AMEX:HBX), a biopharmaceutical company focused on advancing cancer care, announced today the issuance of U.S. Patent No. 6,989,386 on January 24, 2006, from the U.S. Patent and Trademark Office. U.S. Patent No. 6,989,386 is directed to Talotrexin compositions and methods of using Talotrexin compositions. The Company believes the patent significantly strengthens its Talotrexin intellectual property estate. "We are thrilled to have a very strong patent position for our lead product, Talotrexin, and expect additional patents to issue, positioning us with a very firm intellectual property estate," commented Mark Ahn, PhD., President & Chief Executive Officer.
